Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-4262

Cancer Inhibitors Isolated from an African Plant

E-Numbers
E-064-2008-0
E-064-2008-1
E-064-2008-2
Lead Inventors
Beutler, John
Co-Inventors
Ratnayake, Ranjala
Covell, David
Ransom, Tanya
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Stages
Pre-clinical (in vivo)
Lead IC
NCI
ICs
NCI

The National Cancer Institute's Molecular Targets Development Program is seeking parties interested in collaborative research to further develop, evaluate, or commercialize cancer inhibitors isolated from the African plant Phyllanthus englerii. The technology is also available for exclusive or non-exclusive licensing.

This invention involves compounds extracted from the African plant Phyllanthus englerii that have potential cancer-inhibiting activity. Bioassay-guided fractionation of the purified extracts revealed a series of novel chemical entities which are named Englerin A-F. The englerins and their derivatives are useful in the treatment of a number of cancers, particularly renal cancer. The englerins exhibit selective and potent renal cell inhibitory activity in vitro.

These compounds can be recovered in reasonable yield from natural product extracts and are well suited for synthetic chemistry derivativization. A sufficient supply of several analogs was extracted for identification and initial biological characterization. A National Cancer Institute NCI60 anti-cancer screening program confirmed renal-selective activity.

Further R&D Needed:

  • Assess toxicity of the compounds in mice and other experimental animals
  • Studies to determine if therapeutic blood levels of the compound can be obtained.
  • Conduct animal studies to establish efficacy against tumors.

Competitive Advantages:

  • Ability to develop therapeutics for renal and other types of cancer
  • Reasonable yield and recovery of the compounds from the natural product extracts
  • Tractable synthetic chemistry schemes for synthesis of these compounds

Commercial Applications:

Request More Info

Licensing Contacts
Dick, Taryn
taryn.dick@nih.gov

Patents

  • US
    Provisional (PRV) 61/018,938
    Filed on 2008-01-04
    Status: Abandoned
  • US
    Provisional (PRV) 61/082,850
    Filed on 2008-07-23
    Status: Abandoned
  • Austria
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Patent Cooperation Treaty
    Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/088529
    Filed on 2008-12-30
    Status: Expired
  • Australia
    National Stage 2008347299
    Filed on 2008-12-30
    Status: Issued
  • Canada
    National Stage 2711434
    Filed on 2013-12-13
    Status: Issued
  • European Patent
    National Stage 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Japan
    National Stage 2010-541518
    Filed on 2008-12-30
    Status: Issued
  • US Patent 8,410,292
    Filed on 2011-09-22
    Status: Issued
  • Belgium
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Switzerland
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Germany
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Denmark
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Spain
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • France
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • United Kingdom
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Ireland
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Italy
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Luxembourg
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • The Netherlands
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Sweden
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued
  • Norway
    European patent (EP) 08869946.7
    Filed on 2008-12-30
    Status: Issued

Collaborations

  • Licensing